Page last updated: 2024-08-05 11:23:34
acrylamides
An enamide which is acrylamide or a derivative of acrylamide obtained by replacement of one or more of its hydrogens.
ChEBI ID: 22216
Members (8)
| Member | Definition | Role |
|---|---|---|
| acrylamide | A member of the class of acrylamides that results from the formal condensation of acrylic acid with ammonia. | acrylamide |
| furylfuramide | A member of the class of acrylamides that is acrylamide which is substituted at positions 2 and 3 by 2-furyl and 5-nitro-2-furyl groups, respectively (the trans isomer). Formerly used as a food preservative, it was withdrawn from the market following suspicions of carcenogenicity. | (Z)-2-(2-furyl)-3-(5-nitro-2-furyl)acrylamide |
| methacrylamide | methacrylamide | |
| osimertinib | A member of the class of aminopyrimidines that is 4-(1-methylindol-3-yl)pyrimidin-2-amine in which one of the amino hydrogens is replaced by a 2-methoxy-4-[2-(dimethylamino)ethyl](methyl)amino-5-acrylamidophenyl group. Used (as the mesylate salt) for treatment of EGFR T790M mutation positive non-small cell lung cancer. | osimertinib |
| pci 32765 | A member of the class of acrylamides that is (3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine in which the piperidine nitrogen is replaced by an acryloyl group. A selective and covalent inhibitor of the enzyme Bruton's tyrosine kinase, it is used for treatment of B-cell malignancies. | ibrutinib |
| pd168393 | A member of the class of quinazolines carrying bromoanilino and acrylamido substituents at positions 4 and 6 respectively. | PD 168393 |
| poziotinib | A member of the class of quinazolines that is quinazoline substituted by (3,4-dichloro-2-fluorophenyl)amino, [1-(prop-2-enoyl)piperidin-4-yl]oxy, and methoxy groups at positions 4, 6, and 7, respectively. It is a potent and irreversible tyrosine kinase inhibitor targeting EGFR and HER2 with exon 20 insertion mutations. | poziotinib |
| sotorasib | A pyridopyrimidine that is pyrido[2,3-d]pyrimidin-2(1H)-one substituted by 4-methyl-2-(propan-2-yl)pyridin-3-yl, (2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl, fluoro and 2-fluoro-6-hydroxyphenyl groups at positions 1, 4, 6 and 7, respectively. It is approved for the treatment of patients with non-small cell lung cancer having KRAS(G12C) mutations. | sotorasib |
Research
Studies (7,077)
| Timeframe | Studies, Drugs in This Class (%) | All Drugs % |
|---|---|---|
| pre-1990 | 324 (4.58) | 18.7374 |
| 1990's | 424 (5.99) | 18.2507 |
| 2000's | 1,028 (14.53) | 29.6817 |
| 2010's | 2,919 (41.25) | 24.3611 |
| 2020's | 2,382 (33.66) | 2.80 |
Study Types
| Publication Type | Studies, Drugs in This Class (%) | All Drugs (%) |
|---|---|---|
| Trials | 401 (5.49%) | 5.53% |
| Reviews | 673 (9.22%) | 6.00% |
| Case Studies | 561 (7.68%) | 4.05% |
| Observational | 55 (0.75%) | 0.25% |
| Other | 5,611 (76.85%) | 84.16% |